Marketing & Communications

Rep access continues to shrink

Rep access continues to shrink

By

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Marketing tone sinks GSK recruiter

GlaxoSmithKline dismissed a marketer over its approach to clinical trial recruiting.

Study: sales rep limits reduce off-label prescriptions

Study: sales rep limits reduce off-label prescriptions

By

Researchers found that limiting sales rep access and interactions reduces off-label prescriptions for the previously detailed drugs, while also upping off-label prescriptions of the drugs that had not been promoted.

OPDP takes on sales aid for alcohol drug

OPDP takes on sales aid for alcohol drug

By

The advertising watchdog gave drugmaker Alvogen 15 days to make amends.

Agnitio launches Rainmaker marketing tool

Agnitio launches Rainmaker marketing tool

By

The company unveiled the mix-and-match marketing management tool at the Eye for Pharma conference in Barcelona.

US Attorney scrutinizes Copaxone marketing

The US Attorney's Office for the Southern District of New York is examining how Teva has marketed MS drug Copaxone and Parkinson's medication Azilect since 2006.

E-mail increasingly read on mobile devices

Movable Ink reports that 65% of Q4 emails were opened on a tablet or smartphone.

UK GPs like search engines more than pharma sites

A survey of UK-based general practitioners shows industry websites are not a go-to source for information. Reps did not fare well, either.

Louisiana chucks Risperdal settlement

An appeals court says J&J does not have to pay $257.7 million.

Dept. of Justice subpoenas Aegerion

Dept. of Justice subpoenas Aegerion

By

The drugmaker announced Friday that the DOJ wants documents regarding sales and marketing of Juxtapid, its drug for an ultra-rare lipid disorder.

Draft legislation has advertisers on edge

Draft legislation has advertisers on edge

By

Lobbying groups say the ad tax draft proposal could wreak havoc throughout the ad industry and its partners, such as publishers and broadcasters, if it were to go through.

NYT picks apart ADHD

The Gray Lady surveys the landscape of attention deficit disorder marketing.

OPDP not happy with Diclegis promo

OPDP not happy with Diclegis promo

By

The bad-ad watchdog issued an untitled letter to drugmaker Duchesnay in November.

OIG subpoenas United Therapeutics paperwork

The government division is scrutinizing marketing information for three drugs.

Aranesp mailer catches OPDP's attention

Aranesp mailer catches OPDP's attention

By

The marketing watchdog's untitled letter says a direct mailer failed to disclose "material facts" from the warnings and precautions section of the PI.

OPDP letter dings Kadmon for previous violation

OPDP letter dings Kadmon for previous violation

By

The agency's bad-ad warning letter calls the new violations "particularly troubling."

Researcher finds black-box drugs have high Warning Letter risk

EyeonFDA finds that, when it comes to black-boxed drugs' marketing materials, the FDA is more likely to issue Warning Letters than untitled letters.

Ariad hunkers down

Ariad hunkers down

By

The drugmaker's latest financial plans could power it through mid-2015.

Co-pay cards OK for exchanges

Subscribers will be able to use co-pay cards on Obamacare exchanges.

Ariad pulls Iclusig from the market after FDA request

Ariad pulls Iclusig from the market after FDA request

By

The drug company is ceasing US distribution and marketing the leukemia drug after the FDA said it was worried about blood clots among clinical trial patients.

Tylenol's crisis manager Lawrence Foster dies at 88

Lawrence Foster's crisis management strategy has become the touchstone for reputation management. His advice is credited with saving Tylenol from being wiped from the marketplace, despite a deadly tampering crisis.

Analyst: Eisai should hire more Belviq reps

Analyst: Eisai should hire more Belviq reps

By

A Credit Suisse analyst notes that the company will need to make a significant impact to meet even lowered expectations. A possible fix: more sales reps behind Belviq.

Intouch creates HCP content division

Intouch creates HCP content division

By

Growing client demand encouraged the agency to make its HCP content capabilities official.

Business briefs: Healthcare reform, Amgen, Pakistan pharma stance, digital marketing

Despite a possible government standoff, exchanges are coming, as is a proffered rebrand; Amgen signs a university deal in China; Pakistan seeks to rein in pharma; digital marketing is on the rise, research shows

Study reveals doc detail preferences: Hang up the phone

Study reveals doc detail preferences: Hang up the phone

By

Doctors shared their information preferences with CMI/Compas, revealing ways marketers can better pace their communications to max out channels.

Valeant leverages Rx sales force, YouTube for OTC brand

Valeant leverages Rx sales force, YouTube for OTC brand

By

The company is supporting its professional pitch for the acne drug with a micro-targeted marketing strategy.

Business briefs: Abbott, IMS Health, Boehringer, plus healthcare reform

Abbott's Depakote lawsuits roll on; IMS buys mobile health firm's assets; BI shutters a chemical plant; and the healthcare reform back-and-forth continues.

Oncologists still most likely to rebuff sales reps: study

Oncologists still most likely to rebuff sales reps: study

By

Oncologists have the most restrictive access policies, a study shows for the second year in a row. But it's not impossible to book face time with these clinicians.

Business briefs: Pfizer, GlaxoSmithKline, AstraZeneca, Mallinckrodt

Pfizer settles Rapamune lawsuits; Moody's downgrades GSK; Astrazeneca pursues anemia medication; Mallinckrodt drugs gets priority review

Surprise! Researchers find MedLegal isn't social media's enemy

By

Execs told Weber Shandwick that internal hurdles such as insufficient expertise and unclear ROI measures are really what's keeping them from the social-media mix.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters